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Downregulation of Fas Gene Expression in Se´zary
Syndrome Is Associated with Promoter
Hypermethylation
Christine L. Jones1, E. Mary Wain1, Chung-Ching Chu2, Isabella Tosi3, Rosalind Foster4,
Robert C.T. McKenzie1, Sean J. Whittaker1 and Tracey J. Mitchell1
Se´zary Syndrome (SS) is an aggressive leukemic variant of primary cutaneous T-cell lymphoma characterized by
the presence of tumor or Se´zary cells that generally display a mature memory T-cell immunophenotype. Se´zary
cells proliferate poorly and therefore their accumulation may be due to defective T-cell homeostasis involving
resistance to apoptosis. In this study, we analyzed Fas expression in CD4þ lymphocytes at the mRNA and
protein levels in a large cohort of SS patients as compared with healthy controls. Fas mRNA expression was
dysregulated in 34/47 patients, with significant under- and overexpression of Fas mRNA detected in 21 and 13
patients respectively (Po0.01). Examination of cell-surface Fas expression showed correlation with the observed
downregulation of mRNA in CD4þ T cells. Mutational analysis demonstrated that functional FAS gene
mutations are rare. Moreover, 16 SS patients who showed significant under-expression of Fas mRNA also
showed significant positional hypermethylation within the FAS CpG island, which was not present in healthy
controls or SS patients determined to have normal or overexpression of Fas mRNA. These data demonstrate that
dysregulation of Fas expression is a common feature of SS, and provide a rationale for targeted therapies to
restore the extrinsic Fas-dependent apoptotic pathway in this malignancy.
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INTRODUCTION
Se´zary Syndrome (SS) is an aggressive, leukemic variant of
primary cutaneous T-cell lymphoma (CTCL). Clinically SS is
characterized by erythroderma, lymphadenopathy, pruritus,
and presence in the peripheral blood of a clonal population
of malignant T cells with hyper-convoluted, cerebriform
nuclei, known as Se´zary cells (Willemze et al., 2005). The
immunophenotype of Se´zary cells is typically that of a mature
memory T-cell (CD4þ /CD45ROþ ) expressing the skin-
homing marker cutaneous lymphocyte antigen and the
chemokine receptor CCR4, but frequently lacking expression
of other T-cell surface markers such as CD7 and CD26
(Burg et al., 2005).
Unlike other T-cell lymphomas/leukemias such as adult
and childhood T-cell acute lymphoblastic leukemia, which
are commonly associated with balanced chromosomal
translocations, no specific karyotype is associated with SS,
although genetic instability with recurrent ‘‘hotspots’’ of
chromosomal abnormalities are a common feature of the
disease. Of note are frequent deletions within the long arm of
chromosome 10, which harbors the FAS gene. Loss of
heterozygosity at microsatellite markers in 10q23.31 has
been reported by two independent studies in up to 50% of SS
patients (Wain et al., 2005; Vermeer et al., 2008). Loss of 10q
has also been described in several other malignancies and is
associated with tumor progression in prostatic and bladder
carcinomas (Cappellen et al., 1997; Komiya et al., 1996).
The FAS gene, which encodes the death receptor
Fas (CD95/APO-1), is activated by its natural ligand
(FasL/CD95 L) and plays a key role in regulating T-cell
homeostasis, primarily through induction of apoptosis via
activation-induced cell death (AICD). Fas signaling leads to
the formation of a multi-molecular complex called the death-
inducing signaling complex, which in turn triggers a cascade
of caspase activation that constitutes the activation phase of
apoptosis. Induction of an immune response following
antigen challenge leads to rapid clonal expansion and
differentiation of naı¨ve T cells resulting in a large pool of
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effector T cells. During the termination phase of the
immune response, the vast majority of effector T cells are
eliminated by AICD, with only a small proportion surviving
AICD and entering the memory T-cell pool (reviewed by
Krammer et al., 2007). Several studies have revealed
that the Fas system is highly regulated during the phases of
a T-cell immune response. Resting T cells express marginal
amounts of Fas and are resistant to apoptosis (Klas et al.,
1993). During the activation phase, Fas is upregulated
(Ju et al., 1995) although short-term activated effector
T cells remain resistant to AICD (Klas et al., 1993), which is
thought to be due to incomplete death-inducing
signaling complex formation and the presence of high levels
of the apoptosis inhibitor c-FLIP (Kirchhoff et al., 2000;
Schmitz et al., 2004). Long-term activated T cells express
comparable levels of Fas to short-term activated T cells, but
have complete death-inducing signaling complex formation
with concomitant downregulation of c-FLIP expression, and
are therefore sensitive to Fas-mediated AICD (Dhein et al.,
1995).
Given the high frequency of deletion within the FAS gene
locus in SS and the fundamental role of the Fas system in
T-cell homeostasis, Fas is an attractive candidate for a pivotal
role in the pathogenesis of this disease. Studies determining
the molecular basis of Canale–Smith syndrome have shown
that heterozygous FAS mutations are sufficient to compromise
Fas function (Drappa et al., 1996). Somatic FAS gene
mutations have been described in several malignancies,
including multiple myeloma and non-Hodgkin’s lymphoma
(Lee et al., 1999; Park et al., 2001; Takakuwa et al., 2002;
Wohlfart et al., 2004). Somatic FAS gene mutations have
been described rarely in tumor cells isolated from skin lesions
of mycosis fungoides (Dereure et al., 2002; Nagasawa et al.,
2004), which is an indolent form of CTCL. However, it
remains to be determined if these mutations result in loss of
function. To date there are no reports of mutational analysis
of the FAS gene in SS. A recent report has demonstrated
frequent resistance (9/16 cases) to Fas-mediated apoptosis in
freshly isolated primary Se´zary cells (Contassot et al., 2008).
Heterogeneity of Fas expression levels was observed with five
cases showing normal or increased Fas expression, and four
cases showing reduced Fas expression. In cases with normal
or enhanced Fas expression, resistance to apoptosis was
attributed to increased expression of the apoptosis inhibitor
c-FLIP. However, the mechanism mediating reduced Fas
expression was not addressed.
Epigenetic gene silencing through promoter hypermethy-
lation of CpG islands is recognized as an important
mechanism regulating transcriptional silencing of genes,
expression of imprinted genes, and in tumorigenesis (Jones
and Baylin, 2002; Schaefer et al., 2007). Tumor suppressor
genes involved in DNA repair, cell cycling, proliferation, and
apoptotic pathways are commonly inactivated through
hypermethylation in malignancy. The FAS gene contains a
1,072 bp CpG island, which spans the transcriptional start
site and exon 1. Hypermethylation of the FAS gene promoter
has been described in colon, prostatic, and small-cell lung
carcinoma (Santourlidis et al., 2001; Hopkins-Donaldson
et al., 2003; Petak et al., 2003), and associated with
decreased Fas gene expression in these malignancies.
In this study we investigated Fas expression status in tumor
cell populations from patients with SS. We demonstrate that
reduced Fas mRNA and protein expression is common in SS
and can be attributed to a specific pattern of methylation
within the FAS CpG island.
RESULTS
Heterogeneity in tumor cell surface markers
We enriched for tumor cells using negative selection to
remove all non-CD4þ cells from the PBL population. This
was justified by experiments we performed on a subset of
patients to identify the cell subset which included the whole
tumor cell population while excluding as many reactive cells
as possible. We examined CD26 as a potential marker to
further isolate the tumor cell population (Jones et al., 2001).
Fluorescence-activated cell sorting was used to isolate
the CD3þCD4þ /CD45ROþ /CD26 and CD3þCD4þ
/CD45ROþ /CD26þ cell populations from five patients,
and T-plastin mRNA expression levels were used to identify
those populations that contained Se´zary cells (Su et al.,
2003). We detected T-plastin mRNA in both CD26 and
CD26þ subsets, with no significant difference in expression
between the two groups (Figure 1).
Decreased Fas mRNA expression in CD4þ cells from SS
patients
Quantitative reverse transcription PCR (qPCR) was used to
determine Fas mRNA expression levels in CD4þ T cells
isolated from peripheral blood. The expression of Fas mRNA
was measured in 47 SS patients and compared to average
expression levels from 16 healthy controls (Figure 2a). Fas
mRNA expression in the healthy control samples showed
little variation, whereas expression in SS patients was highly
heterogeneous, ranging from a three-fold increase to a
30-fold reduction as compared with healthy controls. Over-
all, 21 samples showed significant underexpression (P¼0.01)
and 13 showed significant overexpression (P¼0.01) of Fas
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Figure 1. Expression of T-plastin mRNA in sorted patient-cell subsets. PBL’s
from five SS patients were sorted into CD3þCD4þ /CD45ROþ /CD26 and
CD3þCD4þ /CD45ROþ /CD26þ subsets then expression of T-plastin
mRNA was quantitated in each subset using qPCR and expressed relative to
the housekeeping gene cyclophilin.
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mRNA. Total lymphocyte count, CD4þ count, and
CD4:CD8 ratio were used to assess tumor burden in all
patients. No correlation between the expression of Fas and
tumor burden or survival was found.
Sequential samples taken at least six months apart were
available from 12 patients, which allowed us to investigate
any changes in Fas mRNA expression over time. Figure 2b
shows the change in expression for each patient between
their first and second samples. The general trend is toward a
decrease in Fas expression over time, which was shown to be
significant using a pairwise t-test (P¼0.021); however, there
is a notable subset of patients who maintained a consistent
level of Fas expression. Total lymphocyte count, CD4þ
count, and CD4:CD8 ratio were recorded at the time of
sampling and are presented in Table 1. There was no
association between the observed decrease in Fas expression
and changes in CD4þ lymphocytes, suggesting that this
decrease is not simply due to an increase in tumor burden.
Loss of cell surface Fas protein in memory T cells from SS
patients
To validate the Fas mRNA expression data, we determined
the level of cell surface protein expression of Fas on the
CD3þCD4þ /CD45ROþ T-cell population by flow cyto-
metry using peripheral blood lymphocytes (PBLs) from 10 SS
patients and six healthy controls. We also examined the cell
surface Fas expression on the Se´zary cell lines SeAx and
HuT78, and the mycosis fungoides cell line MyLa. Figure 3a
shows representative Fas histogram plots for one healthy
individual (H6), two SS patients (P2, P7), and the cell lines.
Whereas HuT78 and MyLa expressed Fas, SeAx displayed
complete absence of cell surface Fas protein.
The proportion of Fas-positive cells within the
CD3þCD4þ /CD45ROþ population was calculated for each
sample (Figure 3b). As expected, nearly all of the memory T
cells in healthy control samples expressed Fas protein on their
cell surface (range: 95.2–99.4% Fasþ ). Patient samples,
however, showed loss of cell surface Fas expression in a
proportion of their memory T cells (range: 1.5–96% Fasþ ).
Patient samples were considered significantly different to
healthy if the proportion of Fas-positive cells within the
CD3þCD4þ /CD45ROþ cell population was less than
80.7% (mean healthy proportion10 standard deviations).
Overall, 7/10 SS patients showed significant loss of Fas cell
surface expression on the memory T-cell population.
To determine whether loss of Fas expression could be used
to identify the tumor cells, we isolated the CD3þCD4þ
/CD45ROþ /Fas- and CD3þCD4þ /CD45ROþ /Fasþ sub-
sets from four patient samples. RNA was extracted and qPCR
10
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Figure 2. Expression of Fas mRNA in SS patient samples. Quantitative
reverse transcription-PCR analysis of Fas mRNA expression in SS samples
expressed as a fold difference in amount of mRNA relative to the mean of 16
healthy controls (RQ). Measurements were performed in triplicate and
normalized against cyclophilin A. (a) Means±99% confidence interval for 47
patient samples. (b) Sequential samples taken from 12 patients between six
months and two years apart to assess the change in Fas mRNA expression over
time.
Table 1. Lymphocyte counts for the 12 SS patients
from whom two sequential samples were obtained
Sample
Total lymphocytes
( 103 ll1)
CD4+ count
(103ll1)
CD4:CD8
ratio
SS5a NA 1.12 8.00
SS5b 8.57 6.74 38.58
SS14a NA 2.27 22.00
SS14b 2.02 1.51 124.33
SS16a NA 0.32 11.00
SS16b 6.65 6.28 108.39
SS18a NA 1.22 11.00
SS18b 3.04 2.34 19.65
SS20a 4.07 3.62 40.41
SS20b 3.21 2.78 24.53
SS21a 6.57 5.89 16.02
SS21b 9.26 8.77 342.00
SS23a 0.61 0.43 9.86
SS23b 1.59 1.33 26.57
SS28a 4.19 3.70 55.25
SS28b 7.79 7.12 53.76
SS31a 6.44 6.08 42.91
SS31b 31.67 31.41 119.48
SS33a 5.04 4.77 80.85
SS33b 5.22 4.92 84.20
SS34a 25.06 24.71 164.33
SS34b 24.85 24.63 198.20
SS46a 1.33 0.67 1.56
SS46b 1.65 0.79 1.61
NA, not available; SS, Se´zary Syndrome.
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used to detect the expression of T-plastin in each subset. Both
subsets had detectable T-plastin expression and there was no
significant difference between the two subsets (data not
shown). We also used RNA from the sorted cell populations
in Figure 1 to determine Fas mRNA expression by qPCR. This
was used to demonstrate the correlation between Fas mRNA
expression and cell surface protein (r¼ 0.816 and
P¼0.00019), which is shown in Figure 3c.
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Figure 3. Flow cytometry analysis of Fas on Se´zary patient cells and cell lines. (a) Histogram plots showing the expression of Fas by one healthy control
(H6), two patients (P2 and P7), and the SeAx, HuT78, and MyLa cell lines. The isotype control is shown with the curve filled in grey. (b) PBLs from six healthy
controls (H1–H6) and 10 patients (P1–P10) were gated on CD3þ , CD4þ , and CD45ROþ and the proportion of Fas-positive cells measured within this
population. The gray line represents the average healthy proportion10 standard deviations. (c) Scatter plot to show the relationship between Fas mean
fluorescent intensity (MFI) and Fas mRNA expression level relative to cyclophilin, the line of best fit is also shown.
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Absence of functional mutations within the FAS coding region
in SS
To establish whether the observed decrease in Fas expression
was due to a genomic mutation, we performed single-strand
conformational polymorphism (SSCP) spanning nine exons
and the 30 end of the promoter of the FAS gene. Abnormal
banding patterns with SSCP as seen in Figure 4a were
identified in 4/20 SS samples. Sequencing of these bands
revealed that one corresponded to a previously reported silent
polymorphism of exon 3 (250A-G), while the other three
anomalies were found to be single-base substitutions within
the promoter region (one 274C-A and two 34A-G).
Single-strand conformational polymorphism analysis of
the promoter and exon 3 was then performed on DNA
extracted from the PBLs of 20 healthy controls to investigate if
the observed substitutions were unique to SS patients. This
revealed a similar rate of detection of the exon 3 polymorph-
ism (1/20) and of promoter region band shifts (2/20).
Sequencing established that the healthy promoter region
band shifts also represented single-base substitutions consist-
ing of one 373C-T and one 295G-A.
Single-strand conformational polymorphism was also
performed on DNA from the SeAx cell line since this had
demonstrated a lack of Fas protein (Figure 3a). Failure to
amplify any of the exons using PCR revealed that the FAS
gene has been deleted in this cell line and further
investigation revealed a complete absence of Fas mRNA
(data not shown). In the two patients who showed minimal
cell surface Fas expression, SSCP analysis revealed loss of
some bands using primer pairs 1.1 (P2a, P2b, and P9), 2 (P2a,
P2b and P9), and 3 (P9). This suggests that allelic loss of some
exons may have occurred in the malignant cells of these
patients (Figure 4b).
Downregulation of Fas mRNA expression in Se´zary patients is
associated with promoter hypermethylation
The FAS gene contains a 1,072 bp CpG island, which spans
the transcriptional start site and first exon of the gene.
Pyrosequencing of bisulfite-converted DNA was used to
assess the methylation status of each of the 74 CpG
dinucleotides in the FAS CpG island. Pyrosequencing is a
quantitative sequencing by synthesis technique (Tost et al.,
2003) and facilitates the analysis of mixed cell populations,
circumventing the need for a specific tumor-cell marker.
We first demonstrated the highly quantitative nature of the
pyrosequencing assays using artificially methylated DNA
mixed in varying proportions with unmethylated DNA.
Average methylation across the CpG island was plotted for
each of these mixtures (Figure 5a); this shows a linear
relationship across the entire range of measurements
(r2¼ 0.99). However, the graph achieved a maximum
methylation measurement of only 80%. We believe this is
due to the CpG methyltransferase reaction not proceeding to
completion rather than any deficiency in the actual measure-
ment. This data suggested that a minimum of 5% tumor cells
displaying methylation could be detected within the reactive
T-cell background.
Methylation of each CpG dinucleotide was then measured
in DNA from 10 healthy control samples and 35 patient
samples comprising 16 who showed downregulation of Fas
mRNA expression, nine who showed normal Fas mRNA
expression, and 10 who showed upregulation of Fas mRNA
expression. Wilcoxon unpaired U-test was used to compare
the methylation in each group of patients with that in healthy
controls at each CpG dinucleotide. In the 16 patients
showing downregulation of Fas mRNA expression, five CpG
dinucleotides (1, 2, 3, 31, and 51 numbered from the start of
the CpG island) were found to have significantly greater
methylation than in healthy controls (Figure 5b). No
significant differences were seen between patients with
normal Fas mRNA expression and healthy controls, or
between patients with upregulation of Fas mRNA expression
and healthy controls in these CpG dinucleotides (data not
shown).
The CpG dinucleotides which showed hypermethylation
in patients with downregulated Fas mRNA expression have
been highlighted on the schematic diagram of the FAS CpG
island shown in Figure 5c. Also highlighted are the NF-kB-
and p53 transcription factor binding sites, which have been
experimentally validated, and the transcriptional start site and
first exon of the gene.
DISCUSSION
This study of a large cohort of SS patients demonstrates that
downregulation of Fas gene expression, associated with
positional methylation of the FAS CpG island, is a common
feature of Se´zary cells.
Our results show a distinct heterogeneity in Fas mRNA
levels with significant underexpression in 21/47 (B45%) and
overexpression in 13/47 (B28%) of patient-derived CD4þ
T cells as compared with healthy controls. These data are
similar to those of a recently published study that reported
Control with mutant primer
Healthy control
Abnormal SSCP pattern
Healthy P2a P2b P9
Figure 4. SSCP analysis of the FAS gene in SS patients. (a) Patient samples
analyzed using primer pair 1.1 for the promoter region demonstrating an
abnormal band shift in one SS patient sample. (b) Sequential samples from
Patient 2 and one sample from Patient 9 who showed minimal cell surface
protein expression of Fas by fluorescence-activated cell sorting; arrows indicate
the decreased intensity of bands in exon two consistent with allelic loss.
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disparity in the levels of Fas expression in a cohort of 16 SS
patients (Contassot et al., 2008). The study by Contassot et al.
focused on the group of patients in whom overexpression of
Fas was demonstrated and showed that resistance to
apoptosis in this group was due to overexpression of c-FLIP.
In addition, those patients with downregulation of Fas
expression also showed resistance to apoptosis, but
the mechanism was not addressed. We sought to investigate
the patient group exhibiting downregulation of Fas as this
was the dominant mode of Fas dysregulation in our
patient cohort.
Follow-up analysis of samples taken at least six months
apart demonstrated a trend for decreased Fas mRNA
expression over time, with the most significant reduction
observed in patients showing increase in disease severity over
time. These findings are consistent with a study demonstrat-
ing an association between loss of Fas protein expression and
aggressive types of CTCL (Zoi-Toli et al., 2000).
Examining cell surface expression of Fas validated the
observed downregulation of Fas mRNA expression in Se´zary
cells. Se´zary cells are generally derived from CD3þCD4þ
/CD45ROþ memory T cells and show variable loss of
expression of CD7 and CD26 (Steinhoff et al., 2008).
At present there are no tumor-specific cell surface biomarkers
available. We found that loss of CD26 does not clearly
distinguish between Se´zary and reactive cell populations
since both CD26 and CD26þ populations contain
detectable T-plastin, a Se´zary-cell-specific mRNA. In healthy
individuals, a large proportion of the CD4þ /CD45ROþ
T-cell population show cell surface Fas expression (Miyawaki
et al., 1992; Muench et al., 2003), which is consistent with
the findings reported here demonstrating Fas expression in at
least 95% of the CD3þCD4þ /CD45ROþ T cells.
In contrast, loss of Fas expression in 7/10 SS patients affected
between 32 and 94% of CD3þCD4þ /CD45ROþ cells
(shown in Figure 3b) and was associated with downregula-
tion at the mRNA level. The detection of tumor cells within
both the Fas and Fasþ subsets (data not shown) and the
CD26 and CD26þ subsets (Figure 1) highlights the marked
heterogeneity present within the tumor cell population,
which we have previously observed in relation to CD25
expression (Tiemessen et al., 2006). Fas expression was
also examined in three CTCL cell lines HuT78, MyLa, and
SeAx. Whereas HuT78 and MyLa cells displayed cell surface
Fas expression, SeAx cells were found to have loss of
expression, which is consistent with the absence of Fas
mRNA expression in this cell line. Loss of cell surface Fas
expression has been reported in several previous studies of
SS, although the underlying mechanism has not established
(Dereure et al., 2000; Osella-Abate et al., 2001; Wu et al.,
2009).
To address putative molecular mechanisms that may
mediate the observed downregulation of Fas in Se´zary cells,
we performed comprehensive mutational scan of the FAS
gene and analyzed the CpG island around the FAS promoter
region for methylation events. Promoter polymorphisms were
identified in 3/20 SS patients and also in some healthy
controls, suggesting that, while the functional relevance of
these polymorphisms are unknown, they are unlikely to
contribute to the downregulation of Fas in SS. The Se´zary cell
line SeAx was found to have a deletion of all exons of the FAS
gene, resulting in complete absence of Fas protein and
mRNA. Loss of multiple exons was also observed in two
SS patients, in whom we found less than 10% of CD4þ
/CD45ROþ T cells displaying surface Fas expression.
However, the commonest finding was the demonstration of
hypermethylation of five specific CpG dinucleotide repeats in
the FAS promoter, which was associated with downregula-
tion of Fas expression.
As a mediator of apoptosis, Fas plays a critical role in
regulating T-cell homeostasis. Heterozygous germ-line muta-
tions of the FAS gene are implicated in the etiology of
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Canale–Smith Syndrome (Drappa et al., 1996), which is
characterized by marked lymphoproliferation and autoim-
munity. FAS is located on chromosome 10q23.31 and 10q is
a frequent region of genomic loss in many malignancies
(Cappellen et al., 1997; Komiya et al., 1996) including CTCL
(Wain et al., 2005; Vermeer et al., 2008). Somatic loss of
function FAS mutations have been described in both
lymphoid (Takakuwa et al., 2002) and non-lymphoid
(Takayama et al., 2002) malignancies, and in some cases
have been found to inhibit Fas ligand induced apoptosis in a
dominant-negative mode (Wohlfart et al., 2004). Two
mutational studies have been performed in mycosis fun-
goides, reporting mutations in 14 and 18% of cases
respectively (Dereure et al., 2002; Nagasawa et al., 2004).
Our study suggests that specific FAS mutations are uncom-
mon in SS, but given that loss of heterozygosity in the region
of 10q23.31 spanning the FAS gene has been detected in
50% of SS patients (Wain et al., 2005; Vermeer et al., 2008),
it is likely that chromosomal deletion/loss may also con-
tribute to loss of Fas protein expression in SS.
Epigenetic events are known to be a critical mechanism of
gene dysregulation in malignancy, and aberrant FAS promo-
ter methylation with associated loss of Fas expression has
previously been described in colon, prostatic, and small-cell
lung carcinoma (Santourlidis et al., 2001; Hopkins-
Donaldson et al., 2003; Petak et al., 2003). Recent studies
of disease-specific methylation events have demonstrated
that complex methylation patterns exist within CpG islands
(Brakensiek et al., 2007). Pyrosequencing of bisulfite-
converted DNA facilitates examination of individual CpG
dinucleotides within a CpG island to allow thorough
evaluation of the methylation status across the whole island
(Tost et al., 2003; Brakensiek et al., 2007; Oprea et al., 2008).
In addition, this technique allows quantitative detection of
changes in methylation in a mixed cell population, and,
therefore, is ideally applicable to the study of SS cells,
overcoming the problems of analysis of a heterogeneous
population of tumor cells admixed with non-malignant cells.
Five hypermethylated CpG dinucleotides within the FAS CpG
island were significantly associated with reduced Fas expres-
sion in SS patients. It is well recognized that the methylation
status of even a single CpG within a CpG island can be
responsible for the control of tissue-specific gene expression
(Aranyi et al., 2005; Kitazawa and Kitazawa, 2007) and for
aberrant gene silencing in cancer (Zou et al., 2006). Three of
the hypermethylated CpG dinucleotides in the FAS promoter
are clustered around the transcriptional start site and,
therefore, could be directly responsible for preventing the
binding of the transcriptional machinery. Furthermore, other
studies of the FAS CpG island have identified hypermethyla-
tion of CpG dinucleotides located at or near transcription
factor binding sites, namely the p53-binding site in colon
carcinoma (Petak et al., 2003) and the NF-kB-binding site in
prostatic carcinoma (Santourlidis et al., 2001). Other
mechanisms by which DNA methylation affects gene
expression include recruitment of methylation binding
domain proteins, which impairs binding of transcriptional
machinery, and recruitment of histone-modifying factors
inducing condensation of the local chromatin structure
(Newell-Price et al., 2000).
At present there is no direct functional evidence to provide
a link between hypermethylation, Fas expression, and
resistance to apoptosis in SS. Such studies require the
availability of suitable cell lines since the demethylating
effect of 50-azacytidine requires cellular proliferation in order
to become incorporated into DNA and prevent maintenance
of methylation. Primary cultures of Se´zary cells do not
proliferate to any significant degree (Berger et al., 2002;
Tiemessen et al., 2006) and, therefore, cannot be used for
such studies. We show that the commonest SS cell lines SeAx
and Hut78, respectively, exhibit homozygous deletion of the
FAS gene and absence of methylation of the FAS CpG island.
However, studies of human colon carcinoma cell lines in
which hypermethylation of Fas and reduced expression has
been found, demonstrate that Fas expression and Fas-
mediated apoptosis can be restored by treatment with
demethylating agents (Petak et al., 2003).
It is now apparent that in addition to loss of heterozygosity
in the FAS gene locus, multiple molecular mechanisms can
mediate Fas dysregulation and resistance to apoptosis in SS.
A recent study (Wu et al., 2009) reported some findings
similar to those reported here, identifying reduced Fas
expression in SS and in CTCL cells from lesional skin of
mycosis fungoides patients. Reduced Fas expression was
shown to correlate with loss of sensitivity to Fas-mediated
apoptosis. Contassot et al. have demonstrated that in SS
patients with overexpression of Fas, resistance to Fas-
mediated apoptosis is still observed and can be attributed
to a concomitant increase in expression of the apoptosis
inhibitory protein c-FLIP. Another study (Klemke et al., 2009)
suggests that attenuated T-cell receptor signaling leading to
loss of FasL upregulation also contributes to apoptosis
resistance in patients with normal expression of Fas.
Fas-mediated apoptosis represents a key mechanism under-
lying activation induced T-cell death. Therefore, these
findings suggest that dysregulation of T-cell homeostasis
may play a pivotal role in the pathogenesis of SS.
In summary, we have identified that loss of Fas receptor on
the surface of malignant T cells is a common feature of SS.
Our data suggest that mutational events are uncommon and
are not linked to the observed loss of Fas expression in the
majority of patients. Significantly, aberrant promoter hyper-
methylation appears to be the most frequent mechanism that
is associated with loss of Fas expression in SS.
MATERIALS AND METHODS
Patient material and cell lines
DNA and cDNA samples derived from Se´zary Syndrome patients
were obtained from a nationally approved research tissue bank (07/
H10712/106), while flow cytometry studies were performed on
freshly isolated PBLs with the approval of the Guy’s and St. Thomas’
Hospital Research Ethics Committee (EC01/301). SS patient blood
samples were obtained during the course of standard clinical
procedures, whereas those from 20 healthy volunteers were
obtained by venepuncture. For all samples, informed consent was
obtained in accordance with the Declaration of Helsinki Principles,
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1975, as revised in 2005. Lymphoprep (Axis-Shield, Kimbolton, UK)
gradient centrifugation was used either directly to isolate PBLs or
following incubation with RosetteSep CD4þ T-cell enrichment
cocktail (Stem Cell Technologies, London, UK) to isolate CD4þ T
cells. We chose to use negative selection in order to avoid activating
the cells and causing any changes in gene expression due to
processing.
All patients had a T-cell clone detected in the peripheral blood as
demonstrated by T-cell receptor V beta and gamma gene rearrange-
ment studies using BIOMED-2 primer sets and fulfilled the
WHO–EORTC diagnostic criteria for SS (Willemze et al., 2005).
Se´zary cell counts were determined at the time of diagnosis and all
patients included in the study had a Se´zary count of greater than
1000 cells/mm3. However, we did not routinely determine Se´zary
counts at the time of patient sampling for our research study, but
relied on measuring total lymphocyte and lymphocyte subset counts,
and using total CD4þ T-cell count and CD4:CD8 ratio as an
indicator of tumor burden.
The cell lines HuT78 and HEK293 were kind gifts from Dr S. John
(King’s College London); SeAx was a kind gift from Dr M. Vermeer
(Leiden University Medical Centre); and MyLa was obtained from
the ECACC (Salisbury, UK). All cultures were maintained in
Roswell’s Park Memorial Institute medium containing 10% fetal calf
serum and 1% penicillin/streptomycin (Invitrogen, Paisley, UK);
SeAx cells were supplemented with 25 U ml1 interleukin-2.
Quantitative RT-PCR
Total RNA was extracted from CD4þ T cells (RNeasy minikit;
Qiagen Ltd, Crawley, UK) and the high-capacity cDNA
archive kit (Applied Biosystems, Warrington, UK) was used to
generate randomly primed cDNA. Quantitative RT-PCR was
performed on the ABI Prism 7000 sequence detection system
(Applied Biosystems) with the following optimized TaqMan probe/
primer sets: Hs00236330 m1–Fas and Hs99999904 m1–cyclophilin
A. Each sample was analyzed in triplicate for both the target gene
(Fas) and an endogenous control (cyclophilin A). The DDCt method
was used to compare the Ct of each patient sample to the mean Ct of
16 healthy control samples after ascertaining that the PCR reactions
for Fas and cyclophilin A proceeded with equal amplification
efficiency.
Flow cytometry
Peripheral blood lymphocytes were incubated with monoclonal
antibodies APC-aCD3 (eBioscience, San Diego, CA), PerCp-aCD4
(BD Biosciences, Erembodegem, Belgium), FITC-aCD45RO (DAKO,
Ely, UK), and PE-aFas (BD Biosciences) or the appropriate isotype
controls (BD Biosciences). Flow cytometry analysis was performed
on a FACSAria II (BD Biosciences) and data were analyzed using
FlowJo software (Tree Star Inc., Ashland, OR). Fluorescence-
activated cell sorting was performed on a FACSAria II (BD
Biosciences) and used the additional antibodies APC-aCD26
(Miltenyi Biotech, Bisley, UK) and PE-Cy7-aCD3 (eBioscience).
SSCP
DNA was isolated from PBLs using standard procedures. PCR was
performed with primer pairs (as described by Beltinger et al. (1998))
designed to amplify all nine exons and the 30 end of the promoter.
PCR products were labeled using a-33PdCTP as previously described
(Scarisbrick et al., 2000). Denatured PCR products were separated
by electrophoresis through polyacrylamide gels containing both 5%
glycerol and no glycerol. A negative control (deionized water) was
performed for each primer pair. DNA from healthy individuals was
used as a positive control.
Sequencing
Abnormal bands were excised from the SSCP polyacrylamide gels.
DNA was eluted, re-amplified, and sequenced using the fmol DNA
Cycle Sequencing System (Promega, Southampton, UK). DNA from
a healthy control was subjected to the same technique and run
simultaneously to ensure reproduction of the published sequence.
Preparation of methylated and unmethylated DNA standards
DNA from the HEK293 cell line was used as completely
unmethylated DNA. An aliquot was subjected to in vitro methylation
using the M. SssI CpG methyltransferase enzyme (NEB, Hitchin, UK)
followed by purification using the MinElute reaction cleanup kit
(Qiagen) to generate completely methylated DNA. Mixtures of
methylated and unmethylated DNA were then prepared prior to
bisulfite treatment.
Bisulfite conversion of DNA
Methylated and unmethylated DNA standards and PBL-derived
genomic DNA from SS patients and healthy controls were bisulfite
treated in 20 ml aliquots containing 1 mg DNA using the EZ DNA
methylation kit (Zymo Research, Orange, CA) according to the
manufacturer’s instructions.
Pyrosequencing
A set of PCR primers specific to bisulfite-treated DNA were designed to
cover the FAS CpG island (available on request). After PCR with one
biotinylated primer, 20ml of PCR product were immobilized onto 4ml
of streptavidin Sepharose HP beads (GE Healthcare, Chalfont St Giles,
UK) and a vacuum prep workstation (Biotage AB, Uppsala, Sweden)
was used to isolate and wash the beads with bound single-stranded
PCR product. These were deposited into a pyrosequencing plate
(Biotage) and the sequencing primer annealed. The pyrosequencing
reaction was carried out using a PSQ HS 96 machine (Biotage)
following the manufacturer’s instructions for methylation analysis. The
PSQ HS 96 software was used to analyze the success of each reaction
and to calculate the corresponding percentage methylation. Data were
exported into an Excel spreadsheet and summarized using a pivot table.
For each of the standards with known methylation, an average was
taken across all the positions measured.
Statistics
All statistical tests were performed using the R statistical software
package (http://www.r-project.org/).
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